- Home
- IMPP vs SPRO Comparison
IMPP vs SPRO Comparison
Compare IMPP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- SPRO
- Stock Information
- Founded
- IMPP 1981
- SPRO 2013
- Country
- IMPP Greece
- SPRO United States
- Employees
- IMPP N/A
- SPRO 32
- Industry
- IMPP Marine Transportation
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- SPRO Health Care
- Exchange
- IMPP Nasdaq
- SPRO Nasdaq
- Market Cap
- IMPP 112.9M
- SPRO 121.0M
- IPO Year
- IMPP N/A
- SPRO 2017
- Fundamental
- Price
- IMPP $3.77
- SPRO $2.01
- Analyst Decision
- IMPP
- SPRO Buy
- Analyst Count
- IMPP 0
- SPRO 4
- Target Price
- IMPP N/A
- SPRO $5.00
- AVG Volume (30 Days)
- IMPP 187.7K
- SPRO 539.9K
- Earning Date
- IMPP 09-05-2025
- SPRO 08-12-2025
- Dividend Yield
- IMPP N/A
- SPRO N/A
- EPS Growth
- IMPP N/A
- SPRO N/A
- EPS
- IMPP 1.02
- SPRO N/A
- Revenue
- IMPP $127,675,263.00
- SPRO $48,576,000.00
- Revenue This Year
- IMPP $8.79
- SPRO N/A
- Revenue Next Year
- IMPP $40.11
- SPRO N/A
- P/E Ratio
- IMPP $3.69
- SPRO N/A
- Revenue Growth
- IMPP N/A
- SPRO N/A
- 52 Week Low
- IMPP $2.12
- SPRO $0.51
- 52 Week High
- IMPP $4.55
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- IMPP 77.89
- SPRO 44.92
- Support Level
- IMPP $3.20
- SPRO $1.83
- Resistance Level
- IMPP $3.50
- SPRO $2.20
- Average True Range (ATR)
- IMPP 0.16
- SPRO 0.10
- MACD
- IMPP 0.05
- SPRO 0.04
- Stochastic Oscillator
- IMPP 86.52
- SPRO 51.62
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.